Osage University has returned for a $75m series B round raised by Arrakis Therapeutics, which has licensed technology from University of Pennsylvania.
US-based biopharmaceutical company Arrakis Therapeutics closed a $75m series B round on Thursday with participation from spinout-focused investment fund Osage University Partners (OUP).
VenBio Partners and Nextech Invest co-led the round, which also featured GV, an early-stage corporate venturing subsidiary of diversified conglomerate Alphabet, and WuXi AppTec Venture Fund, an investment unit of pharmaceutical firm WuXi AppTec.
Alexandria Venture Investments, a corporate venturing arm of life science real estate provider Alexandria Real Estate Equities, also took part, as…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
